Facebook
X
LinkedIn
ForwardNational Marrow Donor Program (NMDP) Enduring Activities
Addressing clinical challenges in AML to optimize treatment plans
In these enduring activities, panelists use case studies to present the latest research on key areas affecting clinical decision-making for patients with acute myelogenous leukemia (AML): risk stratification using patient cytogenetic and molecular markers, optimal timing of treatments for patients in first remission, and exploring treatment options for older patients.
Each enduring activity covers one of the three key areas.
Target audience
Hematologists, oncologists, nurse practitioners, physician assistants, and other health care professionals who treat patients with AML.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and National Marrow Donor Program. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this Enduring Material for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Medical College of Wisconsin designates this activity for up to 3 hour of participation for continuing education for allied health professionals.
Target Audience
Learning Objectives
AML in older adults: Are outcomes age dependent
At the conclusion of this activity, I will be able to:
- Apply evidence-based patient- and disease-specific prognostic factors at diagnosis to identify potential treatment options for patients with AML
- Compare the risks and benefits of therapeutic options, including HCT, for older patients with AML
- Cite recent clinical trial results and the impact of treatment timing and disease status on outcomes for older patients
- Use patient education resources to support the needs of patients and caregivers in understanding treatment choices for older patients
Making AML therapy decisions at first remission: Is timing everything
At the conclusion of this activity, I will be able to:
- Describe cytogenetic and molecular marker-based risk stratification for prognostic and therapeutic decisions for AML in CR1
- Identify the risks and benefits of available therapeutic options and how timing of HCT affects patient outcomes
- Cite recent clinical trial results and the impact of patient- and disease-specific factors on outcomes
- Use patient education resources to support the needs of patients and caregivers in understanding treatment choices
AML risk stratification: Influence of emerging cytogenetics and molecular markers on treatment decisions
At the conclusion of this activity, I will be able to:
- Describe which cytogenetic and molecular marker testing should be completed for patients newly diagnosed with AML
- Cite the latest research that revises categorization for intermediate- or high-risk disease
- Apply cytogenetic and molecular marker risk stratification to inform prognosis and guide therapeutic options
ACCME Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and National Marrow Donor Program. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this Enduring Material for a maximum of 1 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 1 hours of participation for continuing education for allied health professionals.